Synapse - Anthony Mato

Results (236)

Awareness, knowledge, and preferences of United States (US) patients with chronic lymphocytic leukemia (CLL) and their caregivers related to finite duration (FD) therapy and minimal (Measurable) residual disease (MRD)

Meeting Abstract

Koffman, B.; Stewart, C.; Avruch, L.; Bailey, N.; Brumble, R.; Byrd, J. C.; Danilov, A. V.; Davids, M. S.; Furman, R.; Jain, N.; more...
Blood (2021)

Fulltext@MSK | Save

Pirtobrutinib, a next generation, highly selective, non-covalent BTK inhibitor in previously treated mantle cell lymphoma: Updated results from the phase 1/2 BRUIN study

Meeting Abstract

Wang, M.; Shah, N. N.; Alencar, A. J.; Gerson, J. N.; Patel, M. R.; Fakhri, B.; Jurczak, W.; Tan, X. N.; Lewis, K.; Fenske, T. S.; more...
Blood (2021)

Fulltext@MSK | Save

Outcomes of chronic lymphocytic leukemia and Richter Transformation following discontinuation of noncovalent Bruton's Tyrosine Kinase inhibitors

Meeting Abstract

Thompson, M. C.; Coombs, C. C.; Roeker, L. E.; Pagel, J. M.; Jensen, J. L.; Battiato, K. E.; Fox, Y.; Meyer, K.; Bailey, N.; Rhodes, J. M.; more...
Blood (2021)

Fulltext@MSK | Save

Addressing a new challenge in chronic lymphocytic leukemia: Outcomes of therapies after exposure to both a covalent Bruton's Tyrosine Kinase Inhibitor and venetoclax

Meeting Abstract

Thompson, M. C.; Roeker, L. E.; Coombs, C. C.; Jensen, J. L.; Kamdar, M.; Skarbnik, A.; Pagel, J. M.; Bailey, N.; Pu, J. J.; Jacobs, R.; more...
Blood (2021)

Fulltext@MSK | Save

Randomized, phase III study of early intervention with venetoclax and obinutuzumab versus delayed therapy with venetoclax and obinutuzumab in newly diagnosed asymptomatic highrisk patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Evolve CLL/SLL study (SWOG S1925; NCT#04269902)

Meeting Abstract

Stephens, D. M.; Moseley, A.; Hill, B. T.; Pagel, J. M.; Shadman, M.; Fisch, M.; Danilov, A. V.; Ng, D.; Mato, A. R.; Brander, D. M.; more...
Blood (2021)

Fulltext@MSK | Save

A phase 2 study evaluating the addition of ublituximab and umbralisib (U2) to ibrutinib in patients with chronic lymphocytic leukemia (CLL): A minimal residual disease(MRD)-driven, time-limited approach

Meeting Abstract

Roeker, L. E.; Leslie, L. A.; Soumerai, J. D.; Falco, V.; Panton, G.; Zelenetz, A. D.; Falchi, L.; Park, J. H.; Pena-Velasquez, C.; Lebowitz, S.; more...
Blood (2021)

Fulltext@MSK | Save

Quality of life in patients <=70 years of age with chronic lymphocytic leukemia treated frontline with ibrutinibrituximab versus fludarabine cyclophosphamide rituximab: Analysis from ECOG-ACRIN E1912

Meeting Abstract

Pophali, P. A.; Wang, X. V.; Zhao, F.; Kay, N. E.; Hanson, C. A.; Thomas, M. L.; O'Brien, S. M.; Barrientos, J.; Paietta, E. M.; Leis, J. F.; more...
Blood (2021)

Fulltext@MSK | Save

Real-world treatment patterns and outcomes of patients with chronic lymphocytic leukemia (CLL) receiving first-line (1L) therapy in the United States (US)

Meeting Abstract

Mato, A. R.; Ravelo, A.; To, T. M; Schuldt, R.; Biondo, J. M. L.
Blood (2021)

Fulltext@MSK | Save

Pirtobrutinib, a next generation, highly selective, non-covalent BTK inhibitor in previously treated CLL/SLL: Updated results from the phase 1/2 BRUIN study